Literature DB >> 21690286

Synergistic effect of antituberculosis drugs and azoles in vitro against Histoplasma capsulatum var. capsulatum.

Rossana de Aguiar Cordeiro1, Francisca Jakelyne de Farias Marques, Raimunda Sâmia Nogueira Brilhante, Kylvia Rocha de Castro E Silva, Charles Ielpo Mourão, Erica Pacheco Caetano, Maria Auxiliadora Bezerra Fechine, Joyce Fonteles Ribeiro, Débora de Souza Collares Maia Castelo-Branco, Rita Amanda Chaves de Lima, Jacó Ricarte Lima Mesquita, Andre Jalles Monteiro, Francisco Airton Castro Rocha, Marcos Fábio Gadelha Rocha, José Júlio Costa Sidrim.   

Abstract

This study evaluated in vitro interactions of antituberculosis drugs and triazoles against Histoplasma capsulatum. Nine drug combinations, each including an antituberculosis drug (isoniazid, pyrazinamide, or ethambutol) plus a triazole (itraconazole, fluconazole, or voriconazole), were tested against both growth forms of H. capsulatum. Stronger synergistic interactions were seen in isoniazid or pyrazinamide plus triazoles for the mold form and ethambutol plus voriconazole for the yeast-like form. Further studies should evaluate these combinations in vivo.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21690286      PMCID： PMC3165363          DOI： 10.1128/AAC.01471-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome.

Authors:  L J Wheat; P Connolly; M Smedema; E Brizendine; R Hafner
Journal:  Clin Infect Dis       Date:  2001-10-23       Impact factor: 9.079

2.  Synergy, antagonism, and what the chequerboard puts between them.

Authors:  F C Odds
Journal:  J Antimicrob Chemother       Date:  2003-06-12       Impact factor: 5.790

Review 3.  The magic bullets and tuberculosis drug targets.

Authors:  Ying Zhang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2005       Impact factor: 13.820

4.  In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum.

Authors:  R K Li; M A Ciblak; N Nordoff; L Pasarell; D W Warnock; M R McGinnis
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

5.  In vitro inhibitory effect of antituberculosis drugs on clinical and environmental strains of Coccidioides posadasii.

Authors:  Rossana de Aguiar Cordeiro; Raimunda Sâmia Nogueira Brilhante; Marcos Fábio Gadelha Rocha; Maria Auxiliadora Bezerra Fechine; Zoilo Pires de Camargo; José Júlio Costa Sidrim
Journal:  J Antimicrob Chemother       Date:  2006-07-24       Impact factor: 5.790

6.  Detection of Histoplasma capsulatum antigen in Panamanian patients with disseminated histoplasmosis and AIDS.

Authors:  Maria Eugenia Gutierrez; Alfredo Canton; Patricia Connolly; Robert Zarnowski; L Joseph Wheat
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

7.  Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention.

Authors:  J B Bass; L S Farer; P C Hopewell; R O'Brien; R F Jacobs; F Ruben; D E Snider; G Thornton
Journal:  Am J Respir Crit Care Med       Date:  1994-05       Impact factor: 21.405

8.  Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America.

Authors:  L Joseph Wheat; Alison G Freifeld; Martin B Kleiman; John W Baddley; David S McKinsey; James E Loyd; Carol A Kauffman
Journal:  Clin Infect Dis       Date:  2007-08-27       Impact factor: 9.079

Review 9.  Disseminated histoplasmosis with hemophagocytic syndrome in a patient with AIDS: description of one case and review of the Spanish literature.

Authors:  Ana Gil-Brusola; Javier Pemán; María Santos; Miguel Salavert; Jose Lacruz; Miguel Gobernado
Journal:  Rev Iberoam Micol       Date:  2007-12-31       Impact factor: 1.044

10.  In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms.

Authors:  Toru Nakai; Jun Uno; Fumiaki Ikeda; Shuichi Tawara; Kazuko Nishimura; Makoto Miyaji
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191
View more
  3 in total

1.  Antifungal therapeutics for dimorphic fungal pathogens.

Authors:  Kristie D Goughenour; Chad A Rappleye
Journal:  Virulence       Date:  2016-09-19       Impact factor: 5.882

2.  Synthesis and antifungal activity in vitro of isoniazid derivatives against histoplasma capsulatum var. capsulatum.

Authors:  Rossana de Aguiar Cordeiro; Francisca Jakelyne de Farias Marques; Rebecca de Aguiar Cordeiro; Marcos Reinaldo da Silva; Angela Donato Maia Malaquias; Charlline Vládia Silva de Melo; Jair Mafezoli; Maria da Conceição Ferreira de Oliveira; Raimunda Sâmia Nogueira Brilhante; Marcos Fábio Gadelha Rocha; Tereza de Jesus Pinheiro Gomes Bandeira; José Júlio Costa Sidrim
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

3.  Antiretroviral drugs saquinavir and ritonavir reduce inhibitory concentration values of itraconazole against Histoplasma capsulatum strains in vitro.

Authors:  Raimunda Sâmia Nogueira Brilhante; Érica Pacheco Caetano; Giovanna Barbosa Riello; Glaucia Morgana de Melo Guedes; Débora de Souza Collares Maia Castelo-Branco; Maria Auxiliadora Bezerra Fechine; Jonathas Sales de Oliveira; Zoilo Pires de Camargo; Jacó Ricarte Lima de Mesquita; André Jalles Monteiro; Rossana de Aguiar Cordeiro; Marcos Fábio Gadelha Rocha; José Júlio Costa Sidrim
Journal:  Braz J Infect Dis       Date:  2015-12-31       Impact factor: 3.257
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.